Tildrakizumab

• Plaque Psoriasis
• Moderate-to-Severe Psoriasis
• Chronic Plaque Psoriasis

Tildrakizumab (brand name Ilumya) is a humanized IgG1 monoclonal antibody that selectively blocks the p19 subunit of interleukin-23 (IL-23). It is given as a subcutaneous injection for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Compared with older systemic agents, the convenience of a quarterly maintenance schedule and the targeted mechanism make it an attractive option for many patients with chronic, treatment-resistant disease who would prefer not to manage daily oral immunosuppressants.

Mechanism of Action

IL-23 is a heterodimeric cytokine made up of p40 and p19 subunits. It is the master regulator of pathogenic Th17 cell maintenance and differentiation, and the resulting IL-17 and IL-22 release drives the keratinocyte hyperproliferation, epidermal hyperplasia, and neutrophilic inflammation that produce psoriatic plaques. Tildrakizumab binds the p19 subunit specifically and prevents IL-23 from engaging its receptor, while sparing IL-12 (which shares the p40 subunit and is also blocked by ustekinumab).

This selective IL-23 inhibition collapses the downstream Th17 response and produces durable skin clearance with relative preservation of IL-12-driven Th1 immunity that is important for defense against intracellular pathogens such as mycobacteria. Pharmacokinetically, the drug has a long half-life of roughly 23 days, supporting every-12-week maintenance dosing, and its bioavailability after subcutaneous injection is approximately 73 percent. Antibody formation against the drug occurs in a small minority of patients and rarely affects efficacy in clinical trials.

Clinical Use

For moderate-to-severe plaque psoriasis, biologics targeting IL-17 or IL-23 generally offer faster and deeper clearance than older agents such as the TNF inhibitor adalimumab. Within the IL-23 inhibitor class, the alternatives are guselkumab and risankizumab; within the IL-17 class, secukinumab and ixekizumab are widely used.

Selection among these agents is guided by comorbidities (psoriatic arthritis, inflammatory bowel disease, prior failed biologics), dosing convenience, and payer coverage. IL-23 inhibitors are generally preferred over IL-17 agents in patients with concurrent inflammatory bowel disease because IL-17 blockade can paradoxically worsen Crohn disease and ulcerative colitis. IL-17 inhibitors offer faster and somewhat deeper skin clearance and have stronger evidence in axial psoriatic arthritis. Tildrakizumab itself is not approved for psoriatic arthritis, where guselkumab and risankizumab carry specific labels — patients with significant joint involvement may be better served by one of those alternatives or by a JAK inhibitor or TNF blocker.

Methotrexate, cyclosporine, apremilast, and oral retinoids remain useful in selected patients, particularly when biologic access is limited or when topical-only therapy and phototherapy have proven inadequate. The American Academy of Dermatology's psoriasis resources and the National Psoriasis Foundation provide patient-level orientation on the broader treatment landscape.

How to Take It

The loading regimen is 100 mg subcutaneously at week 0 and week 4, followed by 100 mg every 12 weeks. The injection is administered by a healthcare professional in the office at present (it is not currently approved for self-injection in the U.S., unlike most other psoriasis biologics). Prefilled syringes are stored refrigerated and removed approximately 30 minutes before injection to allow them to reach room temperature, which makes administration more comfortable; they should not be shaken at any point.

Injection sites — abdomen, thigh, or upper arm — are rotated to avoid local irritation. Most patients see meaningful improvement by week 8 to 12 and best response by week 28; if response is inadequate by week 28, the drug is generally discontinued in favor of an alternative biologic class. Patients should continue routine skin care and gentle moisturization, and sun protection becomes especially important — see our sun safety Florida guide for practical guidance, since psoriatic skin treated with biologics can be more easily sunburned and the underlying disease may flare with significant sunburn.

Lifestyle factors matter alongside biologic therapy. Smoking cessation, weight management, and treatment of metabolic comorbidities improve psoriasis outcomes and overall cardiovascular risk, which is elevated in patients with significant psoriasis. Limiting alcohol may also help.

Monitoring and Follow-Up

Before starting tildrakizumab, patients are screened for latent tuberculosis with an interferon-gamma release assay or tuberculin skin test, hepatitis B and C serologies, and a complete blood count and comprehensive metabolic panel — see understanding blood work lab panels. Baseline psoriasis area and severity index (PASI) and body surface area involvement provide a yardstick for response.

Annual TB screening continues during therapy, and any new exposure history should prompt repeat testing regardless of timing. Live vaccines (MMR, varicella, yellow fever, live influenza) should be brought up to date before initiation; afterward only inactivated vaccines (inactivated influenza, pneumococcal, recombinant zoster, RSV, COVID-19, hepatitis B as needed) are given. The FDA prescribing information is available through accessdata.fda.gov, and the CDC maintains adult immunization schedules helpful for coordinating biologic therapy with vaccinations. Routine bloodwork during maintenance therapy is generally limited to clinical-event-driven testing.

Special Populations

No dose adjustment is needed for renal or hepatic impairment, because monoclonal antibodies are cleared by the reticuloendothelial system rather than by liver or kidney. Pregnancy data are limited; tildrakizumab is an IgG1 antibody and does cross the placenta in the second and third trimester, so risks and benefits should be weighed individually with input from maternal-fetal medicine. Women planning pregnancy may consider continuing biologics through the early second trimester and then pausing, although some recent guidelines support continuation throughout pregnancy in patients with severe disease where flare would itself harm the pregnancy.

Children under 18 have not been studied with tildrakizumab. Patients with a history of recurrent infections — chronic sinusitis, recurrent UTIs, bronchiectasis — may need additional vigilance and possibly more frequent monitoring. Concurrent use with another biologic or with potent immunosuppressants such as cyclosporine has not been studied formally and is generally avoided due to additive immunosuppression risk.

Lifestyle and Supportive Care

Psoriasis is a systemic inflammatory disease, not just a skin condition; comprehensive care addresses cardiovascular, metabolic, and psychological dimensions alongside skin clearance. The cardiovascular event rate in patients with moderate-to-severe psoriasis is elevated independent of traditional risk factors, and aggressive management of blood pressure, cholesterol, blood glucose, and weight is part of standard care. Mediterranean dietary patterns appear to reduce psoriasis severity and align with cardiovascular risk reduction.

Weight loss in patients with elevated BMI improves both psoriasis activity and biologic response rates — heavier patients sometimes need higher biologic doses or additional weight-based strategies. Smoking cessation reduces disease severity and improves treatment response. Limiting alcohol matters because heavy intake worsens psoriasis and amplifies hepatotoxicity from concomitant systemic therapy. Stress management is meaningful — many patients identify stress as a flare trigger, and mindfulness, exercise, and counseling all help.

Skin care complements systemic therapy: gentle cleansers, fragrance-free moisturizers applied liberally and especially after bathing, lukewarm rather than hot water, and avoidance of harsh exfoliation. Sunscreen use prevents flares from sunburn (the Koebner phenomenon, where new plaques can develop in areas of skin trauma). For patients with scalp involvement, medicated shampoos containing salicylic acid, coal tar, or ketoconazole can supplement systemic therapy. Mental health screening for depression and anxiety is appropriate at every visit because both are markedly more common in psoriasis patients and can themselves worsen disease through stress pathways. Connecting patients with the National Psoriasis Foundation and local support groups reduces isolation. Routine cancer screening should not be deferred during biologic therapy — the absolute risk increase from IL-23 inhibitors appears small or absent, but standard age-appropriate screening (colonoscopy, mammography, cervical cancer screening, skin examination) remains important and may even merit slightly more attention given the chronic immunomodulation.

When to Contact Your Doctor

Fever, chills, persistent cough, or any signs of infection that do not resolve in a few days should prompt a call before the next scheduled dose. Sudden swelling of the face or throat, difficulty breathing, or hives after an injection suggests a hypersensitivity reaction and is a medical emergency. Worsening of psoriasis despite therapy, or new joint pain that could indicate emerging psoriatic arthritis, should also be reported so the treatment plan can be reassessed.

If you have questions about tildrakizumab or your psoriasis treatment plan, our team at Zimmer Medical Group can help — contact us or schedule a visit.